N/A N=301 Tocolysis for Preterm Labor
Preterm Labor
Primary: The Primary Outcome Measure of This Research is to Compare the Efficacy of the Three Clinically Used Tocolytic Agents in a Prospective Study That Will Allow Direct…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor
Obstetric Labour, Premature
Primary: Number of Participants With Vital Sign Values of Potential Clinical Concern — 2; 4; 0; 3 Participants
Phase 2 N=21 Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
Pregnancy Complications
Primary: Number of Participants With Achievement of 34 Weeks Gestation — 0; 0 Participants
Phase 3 N=88 Nifedipine for Acute Tocolysis of Preterm Labor
Preterm Labor
Primary: Number of Participants With Preterm Birth — 24; 20 Participants
N/A N=262 Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor
Threatened Preterm Labor
Primary: Evaluate if ACTH Can be Used as a Predictive Marker for Preterm Labor — 23.4; 19.3 pg/ml — p=<0.001
N/A N=46 Prevention of Preterm Birth With a Pessary in Twin Gestations
Premature Birth · Short Cervix
Primary: Number of Participants With Preterm Delivery — 9; 8 Participants
N/A N=20 Cervix Monitor for Elasticity and Length Measurements
Preterm Birth
Primary: Cervix Elasticity — 54; 19.7 kPa
N/A N=144 The Use of Progesterone to Reduce Preterm Birth
Preterm Birth
Primary: Weeks Gestation at Birth Among Patients Receiving the Active Drug. — 31.9; 30.2 weeks
Phase 3 N=2,831 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Pregnancy · Respiratory Distress Syndrome · Pregnancy Outcomes
Primary: Neonatal Composite Outcome — 165; 202; 145; 184 Participants — p=0.02
N/A N=995 Neonatal Outcome by Reason for Delivery
Preterm Delivery
Primary: Composite Perinatal Morbidity — 277; 203; 221; 45 participants
N/A N=122 Prevention of Preterm Birth With a Pessary in Singleton Gestations
Preterm Birth · Short Cervix
Primary: Number of Subjects Experiencing Preterm Birth — 26; 23 Participants
N/A N=230 Cervical Ripening in Premature Rupture of Membranes
Pregnancy · Premature Rupture of Membranes · Preterm Premature Rupture of Membranes
Primary: Rate of Cesarean Section — 27; 26; 89; 86 participants — p=0.99
Phase 3 N=321 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
Preterm Birth
Primary: Newborn Respiratory Distress Syndrome (RDS) — 44; 18 Twins
N/A N=36 Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor
Obstetric Labor, Premature
Primary: Number of Participants With Delay of Preterm Delivery by 48 Hours. — 15; 21 Participants
Phase 4 N=108 Pitocin or Oral Misoprostol for PROM IOL
PROM
Primary: Time From Induction of Labor (IOL) to Delivery — 18.1; 14.9 Hours
Phase 3 N=1,311 A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
Short Cervical Length
Primary: Number of Participants With Delivery or Fetal Loss of Either Twin Prior to 35 Weeks Gestation — 84; 84; 86 Participants
Phase 2 N=10 Indomethacin Versus Nifedipine for Preterm Labor Tocolysis
Obstetric Labor, Premature
Primary: Count of Patients With Recurrent Preterm Labor Within Two Weeks of Randomization — 2; 1 Participants — p=0.004
Phase 3 N=152 Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
Preterm Delivery
Primary: Gestational Age at Delivery — 29.2; 29.5 weeks.
Phase 4 N=205 Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth
Premature Birth
Primary: Preterm Birth <37 Weeks — 29; 36 Participants
Phase 2 N=482 Reducing Preterm Births in Underserved Pregnant Women
Preterm Birth · Low Birth Weight <2500 Grams · Verylow Birthweight <1500 Grams
Primary: Birthweight — 40; 26 participants
Phase 3 N=465 PREGNANT Short Cervix Trial
Preterm Delivery · Short Cervix · Short Uterine Cervical Length
Primary: Number of Participants With Birth <=32 6/7 Weeks Gestation. — 36; 21 participants — p=0.020
Phase 3 N=1,708 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery
Preterm Birth
Primary: Preterm Birth <35 Weeks Gestation — 66; 122 Participants
Phase 2 N=271 Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
Preterm Birth
Primary: Number of Participants Not Giving Birth Before Week 32 and Week 34 of Gestation — 73; 71; 67; 66 Participants
N/A N=174 Comparing IM vs. Vaginal Progesterone for Pre-term Birth
Infant, Premature · Premature Birth
Primary: Preterm Birth — 29; 30 Participants
N/A N=584 Transperineal Ultrasound to Assess the Progress of Labour
Placenta Praevia · Vaginismus
Primary: Caesarean Delivery — 79 Participants
N/A N=8 Pilot Study to Evaluate a Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions
Preterm Birth
Primary: Uterine Contractions — 3.18; 3.78; 3.20 minutes
N/A N=192 Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial
Obstetric Labor, Premature
Primary: Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence — 80; 72 Participants — p=0.01
N/A N=385 Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix
Preterm Birth
Primary: Spontaneous Delivery Before 34 Completed Weeks — 51; 12 Participants
Phase 3 N=36 Oral Progesterone for Prevention of Preterm Birth
Preterm Birth
Primary: Rate of Recurrent Preterm Birth — 5; 8 participants
N/A N=53 Multifactorial Approach to Emergent Cerclage
Cervical Insufficiency
Primary: Gestational Latency Achieved Between Cerclage Placement and Time of Delivery — 80; 97 days — p=0.018